Wilbanks Smith & Thomas Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,454	Closed	-$53K	–	1211
2018 Q3	$53K	Buy	+2,454	New	+$57K	﹤0.01%	668
2013 Q4	–	Sell	-28,844	Closed	-$1.09M	–	298
2013 Q3	$1.09M	Buy	28,844 +3,689	+15%	+$144K	0.15%	103
2013 Q2	$986K	Buy	+25,155	New	+$980K	0.15%	102

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's TEVA Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 2,454 shares — an estimated $53K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $1.09M in Q3 2013. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Wilbanks Smith & Thomas Asset Management reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 2,454 Teva Pharmaceuticals shares in Q4 2018, an estimated $53K.
Wilbanks Smith & Thomas Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Wilbanks Smith & Thomas Asset Management's Teva Pharmaceuticals position peaked at $1.09M in Q3 2013.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.